"One Medical" made a profit of 2 million in December, and YSB (09885) integration is going smoothly.

On January 14, 2025, YSB (09885) announced the latest progress of the integration of "Yi Kuai Yao" after the completion of the main delivery acquisition at the end of November 2024. From a business perspective, "Yi Kuai Yao" has a stable cooperative relationship with upstream and downstream partners, and its industry position has been further consolidated. Both parties' business and management systems are smoothly integrated; from a financial perspective, the company expects that the unaudited total revenue of "Yi Kuai Yao" in December 2024 will be no less than 100 million yuan, and the unaudited net profit will be no less than 2 million yuan, and it has already achieved profitability. Earlier, some external parties expressed concerns about YSB's acquisition this time, believing that although "Yi Kuai Yao" has a certain market share and customer resources, it has not achieved stable profitability in recent years, and YSB has just turned losses into profits. Concerns were raised that this acquisition might drag down YSB's financial condition and consequently affect its future performance; there were also concerns that this acquisition might shake the cooperation relationship between "Yi Kuai Yao" and its upstream and downstream partners. How YSB ensures the smooth progress of the integration process and whether it can achieve the expected synergies after integration are also the focus of external attention. From the content of this announcement, it can be seen that the integration of both parties is progressing orderly, "Yi Kuai Yao" has achieved results in terms of profitability, and YSB's acquisition this time has achieved phased results. This may gradually dispel external concerns about the profitability and integration risks of this acquisition target. In the long run, YSB's strategic acquisition of "Yi Kuai Yao" this time will undoubtedly bring positive effects on its performance growth.